General Information of the Protein
| Protein ID |
PT02999
|
||||
|---|---|---|---|---|---|
| Protein Name |
Cytochrome P450 26A1
|
||||
| Secondarily Protein Name |
Cytochrome P450 retinoic acid-inactivating 1
Retinoic acid 4-hydroxylase
Retinoic acid-metabolizing cytochrome
|
||||
| Gene Name |
CYP26A1
|
||||
| Secondarily Gene Name |
CYP26
P450RAI1
|
||||
| Sequence |
MGLPALLASALCTFVLPLLLFLAAIKLWDLYCVSGRDRSCALPLPPGTMGFPFFGETLQMVLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGEHRLVSVHWPASVRTILGSGCLSNLHDSSHKQRKKVIMRAFSREALECYVPVITEEVGSSLEQWLSCGERGLLVYPEVKRLMFRIAMRILLGCEPQLAGDGDSEQQLVEAFEEMTRNLFSLPIDVPFSGLYRGMKARNLIHARIEQNIRAKICGLRASEAGQGCKDALQLLIEHSWERGERLDMQALKQSSTELLFGGHETTASAATSLITYLGLYPHVLQKVREELKSKGLLCKSNQDNKLDMEILEQLKYIGCVIKETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDTHDVAEIFTNKEEFNPDRFMLPHPEDASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNGPPTMKTSPTVYPVDNLPARFTHFHGEI
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Enzyme
>
Cytochrome P450
>
Cytochrome P450 family 26
>
Cytochrome P450 family 26A
>
Cytochrome P450 26A1
|
||||
| Function |
A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals (PubMed:22020119, PubMed:9228017, PubMed:9716180). RAs exist as at least four different isomers: all-trans-RA (atRA), 9-cis-RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the biologically active isomer, although 9-cis-RA and 13-cis-RA also have activity (Probable). Catalyzes the hydroxylation of atRA primarily at C-4 and C-18, thereby contributing to the regulation of atRA homeostasis and signaling (PubMed:22020119, PubMed:9228017, PubMed:9716180). Hydroxylation of atRA limits its biological activity and initiates a degradative process leading to its eventual elimination (Probable). Involved in the convertion of atRA to all-trans-4-oxo-RA. Able to metabolize other RAs such as 9-cis, 13-cis and 9,13-di-cis RA (By similarity) (PubMed:9228017). Can oxidize all-trans-13,14-dihydroretinoate (DRA) to metabolites which could include all-trans-4-oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-epoxy-DRA, and all-trans-18-hydroxy-DRA (By similarity). May play a role in the oxidative metabolism of xenobiotics such as tazarotenic acid (PubMed:26937021).
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| HGNC ID | |||||
| Subcellular Location |
Endoplasmic reticulum membrane
Microsome membrane
|
||||
Map of Molecular Bioactivity Related to the Protein
|
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000018 , HL-60
Cell Line ID: CL000063 , Hep-G2
Cell Line ID: CL000083 , MCF-7
Cell Line ID: CL000013 , Sf9
Cell Line ID: CL000078 , T-47D
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Cytochrome P450 26 (CYP26A1) )
| Target Type | Clinical trial Target | ||||
|---|---|---|---|---|---|
| Disease | 2 Target-related Diseases | 2 | |||
| 1 | Dermatological disease [ICD-11: DA24.Y] | ||||
| 2 | Psoriasis vulgaris [ICD-11: EA90] | ||||
| Clinical Trial Drug(s) | 2 Clinical Trial Drugs | 2 | |||
| 1 | LIAROZOLE | Phase 2/3 | |||
| 2 | Rambazole | Phase 2 | |||